Volume 22, Number 5—May 2016
Research
Plasmodium falciparum In Vitro Resistance to Monodesethylamodiaquine, Dakar, Senegal, 2014
Bécaye Fall, Marylin Madamet, Cheikhou Camara, Rémy Amalvict, Mansour Fall, Aminata Nakoulima, Bakary Diatta, Yaya Diémé, Boubacar Wade, and Bruno Pradines
Table
Ex vivo susceptibility to standard antimalarial drugs of 36 Plasmodium falciparum isolates from 44 malaria patients compared with a P. falciparum W2 clone tested under the same conditions, Hôpital Principal de Dakar, Dakar, Senegal, August 2014–December 2014*
| Antimalarial drug | Geometric mean IC50 (95% CI)† |
Ratio of geometric mean IC50 (isolate/W2) | Cutoff for reduced susceptibility† | % Isolates with reduced susceptibility (no./no. tested) | |
|---|---|---|---|---|---|
| Isolates | W2 clone | ||||
| Monodesethylamodiaquine | 25.3 (16.9–38.0) | 70 (66–74) | 0.36 | 61 | 30.6 (11/36) |
| Lumefantrine | 6.8 (4.4–10.8) | 15.4 (11.7–20.3) | 0.44 | 115 | 0 (0/36) |
| Chloroquine | 64.6 (46.2–90.2) | 254 (234–276) | 0.25 | 77 | 52.8 (19/36) |
| Mefloquine | 22.6 (16.9–30.3) | 12.7 (11.5–14.1) | 1.78 | 30 | 44.1 (15/34) |
| Quinine | 80.2 (54.4–118.2) | 262 (247–278) | 0.31 | 611 | 2.8 (1/36) |
| Piperaquine | 36.4 (26.2–50.6) | 34.8 (31.9–37.9) | 1.05 | 135 | 11.8 (4/34) |
| Pyronaridine | 10.5 (7.8–14.1) | 26.0 (23.9–28.3) | 0.40 | 60 | 5.9 (2/34) |
| Dihydroartemisinin | 1.8 (1.17–2.77) | 1.26 (1.05–1.57) | 1.43 | 12 | 2.8 (1/36) |
| Artesunate | 2.5 (1.6–3.7) | 1.19 (1.03–1.41) | 2.10 | 12 | 8.3 (3/36) |
| Doxycycline | 8.5 (5.6–12.7) | 10.4 (9.2–11.7) | 0.82 | 37 | 16.7 (6/33) |
*The geometric mean IC50 values for W2 are the results of 5 independent experiments, in which batches of plates were tested and validated on the chloroquine-resistant W2 strain (Indochina). IC50, 50% inhibitory concentration.
†All IC50 values are given in nmol/L except those for doxycycline, which are given in µmol/L.
Page created: April 13, 2016
Page updated: April 13, 2016
Page reviewed: April 13, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.